The Renal Biomarkers Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Renal Biomarkers Market?
The market size of renal biomarkers has seen significant growth over recent years. The market increased from $1.28 billion in 2024 to $1.38 billion in 2025, showing a compound annual growth rate (CAGR) of 7.8%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Renal Biomarkers Industry?
The Renal Biomarkers Global Market is projected to grow to a size of $1.91 billion by 2029, with a compound annual growth rate (CAGR) of 8.5%.
Download Your Free Sample of the 2025 Renal Biomarkers Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Renal Biomarkers Market?
The key drivers in the renal biomarkers market are:
• Personalized medicine and targeted therapies driving the demand
• The integration of biomarker testing into routine clinical practice
• The emergence of markets in Asia and Latin America
• The utilization of non-invasive biomarker testing methods and continuous monitoring with wearable devices
Global Market Segmentation: Identifying Major Renal Biomarkers Industry Segments
The renal biomarkers market covered in this report is segmented –
1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types
2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)
3) By Application: Diagnosis And Disease Progression Monitoring, Research Homecare
4) By End User: Hospitals, Diagnostic Laboratories, Other End Users
Pre-order the 2025 Renal Biomarkers Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Renal Biomarkers Market?
The key trends in the headache disorders market are:
• The incorporation of biomarker testing into routine clinical procedures is a growing trend.
• Multiplex biomarker panels are emerging for thorough disease profiling.
• The use of artificial intelligence and machine learning for biomarker discovery is on the rise.
• Point-of-care biomarker testing in home healthcare settings is becoming increasingly common.
Who Are the Top Competitors & Leading Players in the Renal Biomarkers Market?
Major companies in the renal biomarkers market are:
• Abbott Laboratories
• BioPorto Diagnostics A/S
• Roche Holding AG
• Thermo Fisher Scientific
• bioMérieux SA
• Randox Laboratories
• Siemens Healthineers
• Beckman Coulter Inc.
• Astute Medical Inc.
• Nexelis Company
• Sphingotec GmbH
• Enzo Biochem Inc.
• PerkinElmer Inc.
• Novartis AG
• Alere Inc.
• AstraZeneca plc
• DiaSorin S.p.A.
• EKF Diagnostics Holdings plc
• Fujirebio Diagnostics Inc.
• Gold Standard Diagnostics Corp.
• Merck KGaA
• Myriad RBM Inc.
• Ortho Clinical Diagnostics Holdings plc
• Quidel Corporation
• R&D Systems Inc.
• Roche Diagnostics International Ltd.
• Sekisui Chemical Co. Ltd.
• Sysmex Corporation
• Tosoh Bioscience Inc.
Regional Dominance: Which Area Leads the Global Renal Biomarkers Market?
North America was the largest region in the renal biomarkers market in 2024
